COLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Collegium Pharmaceutical Inc (COLL) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has demonstrated strong financial growth and positive analyst sentiment, the recent price decline, lack of proprietary trading signals, and neutral technical indicators suggest waiting for a more favorable entry point. The stock is better suited for monitoring rather than immediate action.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 32.656, and moving averages are converging, showing no clear trend. Key support is at 42.146, with resistance at 46.47. The stock closed below its pivot level of 44.308, suggesting weakness.
Strong Q4 2025 financial performance with 24% YoY revenue growth and a 35.31% increase in net income. Analysts have raised price targets recently, citing multi-year growth potential and strong product portfolio momentum.
The stock has experienced a significant price decline (-8.20% pre-market, -3.34% regular market, -0.88% post-market). Q4 non-GAAP EPS missed estimates by $0.10, which may weigh on investor sentiment. Technical indicators show bearish momentum and no clear reversal signals.
In Q4 2025, the company reported revenue growth of 24% YoY to $780.6 million and adjusted EBITDA of $460.5 million. Net income increased by 35.31% YoY to $16.96 million, and gross margin improved to 62.49%. However, non-GAAP EPS of $2.04 missed estimates by $0.10.
Analysts maintain a positive outlook with multiple Buy and Overweight ratings. Recent price target updates range from $55 to $60, reflecting confidence in the company's growth trajectory and product portfolio durability.
